Amgen (AMGN) : The total money flow in Amgen (AMGN) was negative ($4.26 million), showing the domination of sellers in the Monday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $65.75 million. Transactions on upticks were comparatively lower at $61.49 million. The uptick to downtick ratio was 0.94. The total block trades done on upticks were valued at $2.03 million. The total block trades on downticks were valued at $8.79 million. The uptick to the downtick ratio of block trades was 0.23. The money flow during block trades was negative ($6.76 million) when the stock traded with a gain of $59 cent. Amgen (AMGN) was $173.02, an increase of 0.34% over the previous days close.
Shares of Amgen Inc. rose by 1.3% in the last five trading days and 6.92% for the last 4 weeks. Amgen Inc. is up 13.9% in the last 3-month period. Year-to-Date the stock performance stands at 9.01%.
Amgen (NASDAQ:AMGN): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $171.48 and $171.48 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $174.72. The buying momentum continued till the end and the stock did not give up its gains. It closed at $174.58, notching a gain of 0.90% for the day. The total traded volume was 2,784,334 . The stock had closed at $173.02 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Such Annette Louise, officer (VP, Finance and CAO) of Amgen Inc, had unloaded 3,000 shares at an average price of $174.59 in a transaction dated on August 2, 2016. The total value of the transaction was worth $523,770.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.